Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Louise Elkjær Fløe; Inge Marie Svane; Lars Bastholt; Henrik Schmidt

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Translated title of the contribution: Immune checkpoint antibodies increase survival in patients with metastatic melanoma

Louise Elkjær Fløe, Inge Marie Svane, Lars Bastholt, Henrik Schmidt

Department of Clinical Medicine

2 Citations (Scopus)

Abstract

The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

Translated title of the contribution	Immune checkpoint antibodies increase survival in patients with metastatic melanoma
Original language	Danish
Article number	V01160070
Journal	Ugeskrift for Laeger
Volume	178
Number of pages	4
ISSN	0041-5782
Publication status	Published - 2016

Keywords

English Abstract
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://ugeskriftet.dk/videnskab/immuncheckpointantistoffer-oeger-overlevelsen-patienter-med-metastatisk-melanom

Cite this

@article{3fa8b083af994490bf5ea516165d0a85,

title = "Immuncheckpointantistoffer {\o}ger overlevelsen for patienter med metastatisk melanom",

abstract = "The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.",

keywords = "English Abstract, Journal Article",

author = "Fl{\o}e, {Louise Elkj{\ae}r} and Svane, {Inge Marie} and Lars Bastholt and Henrik Schmidt",

year = "2016",

language = "Dansk",

volume = "178",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

}

TY - JOUR

T1 - Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

AU - Fløe, Louise Elkjær

AU - Svane, Inge Marie

AU - Bastholt, Lars

AU - Schmidt, Henrik

PY - 2016

Y1 - 2016

N2 - The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

AB - The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 27550784

SN - 0041-5782

VL - 178

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V01160070

ER -

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this